Kinase Domain Point Mutations in Ph+ Acute Lymphoblastic Leukemia (ALL) Emerge Following Therapy with BCR-ABL Kinase Inhibitors

BACKGROUND: BCR-ABL kinase domain (KD) mutations are detected in approximately 45% of imatinib-resistant CML. Patterns of KD mutations in Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) are less well-studied. METHODS: We assessed KD mutations in relapsed Ph+ ALL following treatments...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Jones, Dan, Thomas, Deborah, Yin, C. Cameron, O'Brien, Susan, Cortes, Jorge E., Jabbour, Elias, Breeden, Megan, Giles, Francis J., Zhao, Weiqiang, Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado: 2008
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4204653/
https://ncbi.nlm.nih.gov/pubmed/18615627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23666
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares